TECH BIO-TECHNE Corp

Nasdaq bio-techne.com


$ 61.20 $ 2.02 (3.39 %)    

Thursday, 16-Oct-2025 18:00:52 EDT
QQQ $ 597.47 $ -2.23 (-0.37 %)
DIA $ 458.55 $ -3.15 (-0.68 %)
SPY $ 658.17 $ -4.53 (-0.68 %)
TLT $ 91.42 $ 0.68 (0.75 %)
GLD $ 401.40 $ 9.06 (2.34 %)
$ 61.6
$ 59.90
$ 57.29 x 2
$ 62.09 x 3
$ 59.61 - $ 62.37
$ 45.87 - $ 80.37
1,797,255
na
9.58B
$ 1.26
$ 130.54
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-22-2025 06-30-2025 10-K
2 05-08-2025 03-31-2025 10-Q
3 02-06-2025 12-31-2024 10-Q
4 11-05-2024 09-30-2024 10-Q
5 08-22-2024 06-30-2024 10-K
6 05-06-2024 03-31-2024 10-Q
7 02-07-2024 12-31-2023 10-Q
8 11-07-2023 09-30-2023 10-Q
9 08-23-2023 06-30-2023 10-K
10 05-08-2023 03-31-2023 10-Q
11 02-07-2023 12-31-2022 10-Q
12 11-07-2022 09-30-2022 10-Q
13 08-24-2022 06-30-2022 10-K
14 05-09-2022 03-31-2022 10-Q
15 02-07-2022 12-31-2021 10-Q
16 11-08-2021 09-30-2021 10-Q
17 08-25-2021 06-30-2021 10-K
18 05-07-2021 03-31-2021 10-Q
19 02-08-2021 12-31-2020 10-Q
20 11-09-2020 09-30-2020 10-Q
21 08-26-2020 06-30-2020 10-K
22 05-11-2020 03-31-2020 10-Q
23 02-06-2020 12-31-2019 10-Q
24 11-06-2019 09-30-2019 10-Q
25 08-28-2019 06-30-2019 10-K
26 05-07-2019 03-31-2019 10-Q
27 02-07-2019 12-31-2018 10-Q
28 11-07-2018 09-30-2018 10-Q
29 08-27-2018 06-30-2018 10-K
30 05-09-2018 03-31-2018 10-Q
31 02-08-2018 12-31-2017 10-Q
32 11-09-2017 09-30-2017 10-Q
33 09-07-2017 06-30-2017 10-K
34 05-10-2017 03-31-2017 10-Q
35 02-09-2017 12-31-2016 10-Q
36 11-09-2016 09-30-2016 10-Q
37 08-29-2016 06-30-2016 10-K
38 05-10-2016 03-31-2016 10-Q
39 02-09-2016 12-31-2015 10-Q
40 11-09-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 td-cowen-maintains-buy-on-bio-techne-raises-price-target-to-70

TD Cowen analyst Kyle Boucher maintains Bio-Techne (NASDAQ:TECH) with a Buy and raises the price target from $65 to $70.

 evercore-isi-group-maintains-outperform-on-bio-techne-raises-price-target-to-72

Evercore ISI Group analyst Daniel Markowitz maintains Bio-Techne (NASDAQ:TECH) with a Outperform and raises the price target...

 trump-pfizer-deal-pushes-health-care-stocks-to-best-rally-in-5-years

Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tari...

 bio-techne-advances-spatial-biology-portfolio-for-rnascope-ish-technology-and-lunaphore-comet

RNAscope™ technology and the Lunaphore COMET™ enable simultaneous RNA and protein detection on the same tissue sectionTechnolog...

 bio-techne-stock-upgraded-as-analyst-flags-attractive-entry-point

RBC Capital upgraded Bio-Techne, citing M&A confidence, margin gains, and growth potential after a sharp stock drop and ali...

 rbc-capital-upgrades-bio-techne-to-outperform-raises-price-target-to-73

RBC Capital analyst Conor McNamara upgrades Bio-Techne (NASDAQ:TECH) from Sector Perform to Outperform and raises the price ...

 citigroup-upgrades-bio-techne-to-buy-raises-price-target-to-70

Citigroup analyst Patrick Donnelly upgrades Bio-Techne (NASDAQ:TECH) from Neutral to Buy and raises the price target from $5...

 rbc-capital-maintains-sector-perform-on-bio-techne-lowers-price-target-to-61

RBC Capital analyst Conor McNamara maintains Bio-Techne (NASDAQ:TECH) with a Sector Perform and lowers the price target from...

 bio-techne-q4-adj-eps-053-beats-050-estimate-sales-316964m-beat-316004m-estimate

Bio-Techne (NASDAQ:TECH) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.50 by 5...

 bio-techne-corporation-announces-agreement-where-mdxhealth-sa-will-acquire-its-exosome-diagnostics-inc-business-including-the-exodx-prostate-test-clia-certified-clinical-laboratory-and-related-assets-under-agreement-bio-techne-will-receive-5m-in-mdxh-stock

Bio-Techne Corporation (NASDAQ:TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION